
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026
TG Therapeutics ranked number 5 on the 2026 Deloitte Technology Fast 500 list of fastest-growing North American companies.
Nasdaq: $TGTXBRIUMVI commercial growthSubcutaneous Phase 3Leverage and investment
TGTX Stock Hub: TG Therapeutics News, BRIUMVI and Subcutaneous Trials
Third-quarter revenue reached $259.9M and full-year guidance rose to about $1B. Net income was $55.5M, BRIUMVI U.S. sales rose about 52% and the company bought back about $100M of stock. Subcutaneous Phase 3 topline and the cost of building that launch are the next tests.
Full research report · PDF
TG Therapeutics ($TGTX), research updated November 18, 2026
19 pages covering BRIUMVI sales and guidance, the third-quarter 2026 results and Form 10-Q, ENHANCE and subcutaneous development, the Blue Owl term loan, buybacks and the share count, with the Health Score and the catalyst map. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next catalyst
Year-end 2026 or Q1 2027 · subcutaneous BRIUMVI Phase 3 topline
TG Therapeutics reported third-quarter 2026 results on November 9 and raised its full-year total revenue target to approximately $1 billion. The next dated item in the company’s own guidance is subcutaneous BRIUMVI Phase 3 topline, guided to year-end 2026 or early 2027. Third-quarter release
Then: a simplified single-infusion IV initiation with a potential launch in mid-2027 and subcutaneous BRIUMVI with a potential launch in 2028, both subject to FDA approval. Phase 2 programs in myasthenia gravis and treatment-resistant schizophrenia are under way without guided readout dates.
TGTX stock at a glance
Chart analysis · JC
Technical chart analysis of $TGTX with bull and bear scenarios on JC Just Charts.
Total revenue · Q3 2026
$259.9M
$161.7M in the same quarter of 2025, a 61% increase, of which $240.0M was net product revenue. Over nine months, $705.2M against $423.7M. Company release
Net income · Q3 2026
$55.5M
Operating income $85.9M against $29.4M a year earlier; $0.39 per basic share. The prior-year quarter included a $365.0M non-recurring tax benefit. Company release
Research and development · Q3 2026
$51.3M
$40.9M a year earlier, driven by subcutaneous manufacturing and secondary-manufacturer costs. SG&A was $80.7M against $63.4M. Company release
Interest expense · Q3 2026
$15.8M
$6.7M a year earlier; operating income covered it about five times. A $9.2M loss on extinguishment of debt was booked in the first quarter. Company release
2026 revenue guidance · raised
~$1B
Total global revenue, raised on November 9 from approximately $950M. BRIUMVI U.S. net product revenue target raised to approximately $915–920M from $890–905M. Company release
Cash + investments · September 30, 2026
$556.7M
Against $612.3M at June 30 and $199.5M at December 31, 2025, after about $100M of share repurchases in the quarter. Company release
Shares outstanding · November 4, 2026
151,147,827
Cover of the Q3 2026 Form 10-Q, against 153,069,053 at August 3. 2,023,452 shares were repurchased in the third quarter at an average $49.43. Form 10-Q
Where TG Therapeutics stands now
Third-quarter 2026 total revenue was $259.9M, including $232.6M of BRIUMVI U.S. net product revenue, up about 52% year on year, and net income of $55.5M. Cash, cash equivalents and investment securities were $556.7M at September 30 against $612.3M at June 30, after about $100M of share repurchases in the quarter. On November 9 the company raised full-year 2026 total revenue guidance to approximately $1B and BRIUMVI U.S. guidance to approximately $915–920M.
One product carries the revenue, and the next value step is clinical.
BRIUMVI U.S. sales supplied about 97% of net product revenue in the quarter and the rest was BRIUMVI sold to the ex-U.S. partner, so pricing, competition and formulary access matter more than pipeline news. Interest expense was $15.8M against $6.7M a year earlier, and subcutaneous manufacturing costs precede any approval.
The constructive case
Guidance has been raised three times in 2026, in May, August and November, and the business now runs at an operating profit: operating income was $85.9M against $29.4M a year earlier, and about $300M of stock has been repurchased across the company’s two programs. A positive subcutaneous Phase 3 would add an administration route the intravenous product does not have, and the single-infusion ENHANCE data support a simpler start.
The cautious case
A single product and a single disease family leave little room for an execution miss, while R&D of $51.3M and SG&A of $80.7M in the quarter show how much spending the growth requires. The subcutaneous program has no approval date, launch costs come before revenue, and the secured term loan keeps $15.8M of quarterly interest in the model.
Latest TG Therapeutics news
Nov 18, 2026
TG Therapeutics ranked number 5 on 2026 Deloitte Technology Fast 500
TG Therapeutics announced it ranked number 5 on the 2026 Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The Company's growth between fiscal years 2022 to 2025 was fueled by BRIUMVI revenues. BRIUMVI was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022.
Nov 10, 2026
Evercore ISI lowers TG Therapeutics price target to $71 from $73
Evercore ISI cut its price target on TG Therapeutics to $71 from $73. The firm kept its Outperform rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 9, 2026
TG Therapeutics reports third quarter 2026 financial results and raises full-year revenue guidance
TG Therapeutics reported its third quarter 2026 financial results and raised its full-year revenue guidance.
Nov 2, 2026
TG Therapeutics to host conference call on third quarter 2026 results
TG Therapeutics will hold a conference call on Monday, November 9, 2026, to discuss third quarter 2026 results and provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. A live webcast will be available on the Events page of the company's website, with an audio replay available for 30 days after the call. The company will issue a press release with its financial results before the call.
Oct 27, 2026
BlackRock amendment reports a September position
BlackRock reported 21,190,534 shares beneficially owned, 13.8%, for September 30 in its October 27 Schedule 13G/A. Sole voting power was 20,848,777 shares. The filing is a dated ownership disclosure, not proof of buying on the filing date or a control campaign.
Oct 23, 2026
Early azer-cel data in progressive MS presented
The ongoing open-label Phase 1 study treated 26 participants. The presentation highlights report EDSS stable or improved in 16 of 18 evaluable participants at Day 90, no dose-limiting toxicities and no high-grade CAR-T toxicities in the reported categories. Small numbers, short follow-up and no control group limit interpretation.
TGTX stock catalysts and operating watchpoints
- November 9, 2026 · reported — Third-quarter 2026 results: total revenue $259.9M, net income $55.5M, 2026 total revenue guidance raised to approximately $1B. Reported
- Year-end 2026 or early 2027 — Subcutaneous BRIUMVI Phase 3 topline in the company guidance. Company data window
- Mid-2027 · potential — Launch of simplified single-infusion IV initiation, if the ENHANCE submission is approved. Company expectation
- 2028 · potential — Subcutaneous BRIUMVI launch, subject to Phase 3 results and FDA approval. Company expectation
- Ongoing — Azer-cel dose escalation and longer follow-up; Phase 2 in myasthenia gravis and Phase 2 in treatment-resistant schizophrenia under way. Clinical follow-up
Third-quarter 2026 release; Form 8-K, November 9, 2026; Company releases; ENHANCE topline
Subcutaneous BRIUMVI: the next test
The subcutaneous program is the largest single call option TG Therapeutics owns, and it is also where much of the pre-approval spending is going. Research and development was $51.3 million in the third quarter against $40.9 million a year earlier, driven by subcutaneous manufacturing and secondary-manufacturer expenses.
Topline data from the fully enrolled Phase 3 trial are guided to year-end 2026 or the first quarter of 2027, and the company points to a potential launch in 2028, subject to FDA approval. Chapter 07 below sets out the Phase 1 data and the Phase 3 design.
Third-quarter 2026 at a glance
Total revenue was $259.9 million, up 60.8% from $161.7 million a year earlier, with operating income of $85.9 million and net income of $55.5 million. Total gross margin was approximately 84%, with BRIUMVI U.S. at approximately 87%, according to the Form 10-Q. Net cash provided by operating activities was $66.6 million over the nine months, against $44.4 million used a year earlier. Chapter 10 gives the line-by-line detail.
TG Therapeutics deep dive: the full analysis
The dated PDF research is collected in the Merlintrader Research Library: Biotech. The chapters below go through the company in detail: 01 TG Therapeutics in November 2026; What Would Falsify This Reading; 02 BRIUMVI: The Label, the Dosing and the Safety Section; 03 ULTIMATE I and II: What the Registrational Data Established, and What It Did Not; 04 The Commercial Ramp and What It Is Doing to the Balance Sheet; 05 Guidance Raised Three Times, and the Run-Rate Claim; 06 ENHANCE, the Consolidated Infusion, and Why There Is No PDUFA Date; 07 Subcutaneous BRIUMVI: The Largest Call Option the Company Owns; 08 Myasthenia Gravis, Schizophrenia and What Is No Longer in the Pipeline; 09 Azer-cel: The Only Asset That Is Not Ublituximab; 10 The Third Quarter of 2026, Line by Line; 11 The Blue Owl Loan and a Balance Sheet That Changed Shape; 12 A Share Count That Is Shrinking, and Q2 and Q3 Buyback Activity; 13 Market Data, Ownership and Retail Sentiment; 14 The Anti-CD20 Field and Where BRIUMVI Sits in It; 15 The Catalyst Map to 2028; 16 Risks and Red Flags. Every figure carries its date and its primary source. The same research is available as a downloadable PDF in the Research Library.
01 TG Therapeutics in November 2026
November 9, 2026. Third-quarter total revenue was $259.9 million against $161.7 million a year earlier, operating income $85.9 million and net income $55.5 million, and the company raised its 2026 total revenue target to approximately $1 billion. The gap between revenue growth and earnings seen in the second quarter, when operating income was $21.7 million on $240.3 million of revenue, narrowed in the third: research and development fell to $51.3 million from $95.3 million in the second quarter. Q3 release.
Revenue rose 60.8% in the third quarter and operating income reached $85.9 million, against $29.4 million a year earlier. Research and development was $51.3 million against $40.9 million a year earlier, reflecting subcutaneous manufacturing and second-manufacturer costs. Higher cost of revenue and interest expense also weighed on profitability.
The company describes itself as a fully integrated commercial-stage biotechnology company focused on B-cell diseases. The practical translation, as of November 2026, is one approved product carrying the whole income statement, three separate attempts to widen it, and a $750 million term loan sitting behind all of it.
What Would Falsify This Reading
The assessment depends on continued product demand, effective development investment and manageable financing costs. The following observations would test it; none is a prediction.
- The BRIUMVI ramp slows. Net product revenue was a calculated $240.0 million in the third quarter of 2026 ($259.936 million total less $19.893 million of license, milestone, royalty and other revenue), against a calculated $159.3 million a year earlier. Flat or falling quarterly sales would warrant investigation into underlying demand, timing, channel inventory and net pricing. A sustained slowdown without corresponding cost adjustment would weaken the spending case; one quarter alone would not show that outcome.
- The subcutaneous program fails to deliver. R&D spending includes work across several programs and manufacturing activities. An unsuccessful subcutaneous (SC) study would weaken a major part of the development case and could leave manufacturing investment underutilized. It would not by itself prove that all research spending was wasted or that the approved IV franchise has failed.
- The debt becomes the constraint. Interest expense rose to $15.8 million in the third quarter from $6.7 million, with a $9.2 million loss on extinguishment of debt booked in the first quarter. The company held $556.7 million of cash and investments at September 30, 2026 and generated $66.6 million of operating cash in the first nine months. A refinancing on worse terms, or a covenant issue, would turn a financing cost into a strategic limit.
- Operating cash flow deteriorates. Nine-month operating cash flow improved from $44.4 million used in 2025 to $66.6 million generated in 2026. A reversal would require a bridge separating working-capital timing from recurring cash earnings and investment. Persistent consumption would weaken the self-funding case; a single negative quarter would not settle it.
These are observations to evaluate alongside their causes and duration, not automatic invalidation rules or predictions.
02 BRIUMVI: The Label, the Dosing and the Safety Section
BRIUMVI is a glycoengineered monoclonal antibody directed at a specific epitope on CD20-expressing B cells. The removal of certain sugar molecules from the antibody, which the company calls glycoengineering, is intended to allow efficient B-cell depletion at lower doses. That is the mechanistic claim; what matters commercially is the label.
The United States indication, in the exact words of the prescribing information in force, reads: “BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.” The application is BLA 761238, approved on December 28, 2022 under standard review, with the United States launch in January 2023.
The EU authorization was granted on May 31, 2023 after the positive opinion of March 30, 2023 from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The indication covers adults with active relapsing MS defined by clinical or imaging features. The authorization holder is Neuraxpharm Pharmaceuticals S.L.
Dosing, from Table 1 of the label, is the operational fact that shapes the whole pipeline strategy: a first infusion of 150 mg over four hours, a second infusion of 450 mg two weeks later over one hour, then 450 mg at week 24 after the first infusion and every 24 weeks thereafter, over one hour. Two visits initiate treatment; maintenance follows the label’s 24-week schedule. The three programs described further down this page — the consolidated single infusion, the subcutaneous formulation and the autoinjector — all exist to shorten that.
The safety section is not decorative and belongs in any honest description of the asset. In the multiple sclerosis trials, infusion reactions occurred in 48 percent of premedicated patients, with 0.6 percent serious. The overall infection rate was 56 percent against 54 percent on teriflunomide, serious infections 5 percent against 3 percent, and there were three infection-related deaths among BRIUMVI-treated patients. The label carries contraindications in active hepatitis B and in patients with a history of life-threatening infusion reaction, and warnings covering hepatitis B reactivation, progressive multifocal leukoencephalopathy, reduction in immunoglobulins and, added in the most recent revisions, clinically significant liver injury reported in the post-marketing setting for anti-CD20 therapies approved in multiple sclerosis, BRIUMVI included.
Recent label supplements include two approvals on August 18, 2025 and one on January 16, 2026. Changes include dosing, administration and warnings. The current U.S. label should be consulted for the applicable wording. The company reports biological exclusivity through December 2034 and patent protection extending to 2042. FDA approval and supplement history.
03 ULTIMATE I and II: What the Registrational Data Established, and What It Did Not
Approval rests on two trials, ULTIMATE I and ULTIMATE II, of identical design: randomized, double-blind, double-dummy, parallel-group, active-comparator studies running 96 weeks in patients with relapsing multiple sclerosis. Patients received either BRIUMVI intravenously with an oral placebo, or teriflunomide 14 mg orally once a day with an intravenous placebo. Entry required at least one relapse in the prior year, or two in the prior two years, or a gadolinium-enhancing lesion in the prior year, with a baseline EDSS between 0 and 5.5.
ULTIMATE I randomized 549 patients, ULTIMATE II randomized 545. The primary endpoint in both was the annualized relapse rate.
In ULTIMATE I, the annualized relapse rate was 0.076 on BRIUMVI against 0.188 on teriflunomide, a 59 percent relative reduction, p<0.001. In ULTIMATE II it was 0.091 against 0.178, a 49 percent relative reduction, p=0.002. The imaging endpoints were more emphatic still: gadolinium-enhancing T1 lesions per scan at week 96 fell by 97 percent in both trials, and new or enlarging T2 lesions by 92 and 90 percent respectively, all at p<0.001.
The disability endpoint did not read out positive, and that matters. In the pooled analysis of both trials, confirmed disability progression at 12 weeks was 5.2 percent on BRIUMVI against 5.9 percent on teriflunomide, a 16 percent risk reduction with p=0.510. The prescribing information states it plainly: there was no statistically significant difference in disability progression between the two arms. The published New England Journal of Medicine analysis gives the same result as a hazard ratio of 0.84 with a 95 percent confidence interval from 0.50 to 1.41.
These studies established relapse and lesion effects versus teriflunomide, but did not show a statistically significant pooled disability-progression difference. This result does not show the performance of every anti-CD20 drug or answer whether a different molecule works in progressive disease.
FDA-label per-trial relapse rates and the EMA public-summary figures use different presentations of the evidence. They are not interchangeable and cannot simply be added together.
04 The Commercial Ramp and What It Is Doing to the Balance Sheet
Full-year 2025 global revenue was $616.3 million, including $594.1 million of U.S. BRIUMVI net revenue. Fourth-quarter and full-year 2025 results, February 26, 2026.
U.S. BRIUMVI net product revenue was approximately $233 million in the third quarter of 2026, according to the November 9 release, which raised full-year BRIUMVI guidance to approximately $915–920 million. The $159.317 million comparative in the income statement is total product revenue, including partner sales, not U.S.-only revenue. U.S. BRIUMVI net revenue was $182.7 million in the fourth quarter of 2025 and $594.1 million for full-year 2025.
Receivables were $416.821 million at September 30, while current inventory was $194.319 million, against $125.586 million at December 31, 2025. Closing receivables divided by quarterly revenue and multiplied by 90 gives roughly 144 days (Merlintrader calculation): a simple balance-to-sales proxy, not a reported collection period or days sales outstanding based on average balances. The company notes that collection of receivables from customers on extended payment terms affects its cash needs, and it recorded no allowance for expected credit losses because the receivables were due from large, established, creditworthy customers.
Gross margin calculated on total revenue was 83.8%, a calculated $217.857 million of gross profit, against about 83% a year earlier; the company describes the third-quarter total gross margin as approximately 84%, with U.S. BRIUMVI at about 87%. According to the June 30 Form 10-Q, LFB royalty expense was $24.4 million in the second quarter and $45.0 million in the first half, with $24.3 million payable at June 30. The agreement describes tiered mid- to high-single-digit rates on worldwide net sales. The expense must not be divided by TG’s U.S. revenue to infer a contractual royalty rate: the disclosed bases differ.
Outside the United States, the model is different and much smaller. TG sells product to Neuraxpharm, which holds the European marketing authorization and commercializes there, and receives a royalty in return. In the third quarter that was $7.4 million of product sales, in addition to a royalty. No sell-through figure for the European market is published by TG, so the size of BRIUMVI’s actual European business is not verifiable from the company’s own disclosures.
Global quarterly revenue
161.709MQ3 2025
259.936MQ3 2026
USD millions; total revenue including partner and license income.
Source: TG SEC · Q3 2026
05 Guidance Raised Three Times, and the Run-Rate Claim
Third raise, November 9, 2026. With the third-quarter results the company raised its 2026 total global revenue target to approximately $1 billion, from approximately $950 million, and its BRIUMVI U.S. net product revenue target to approximately $915–920 million, from $890–905 million, and reaffirmed operating expense guidance (research and development and SG&A excluding non-cash compensation) of approximately $450–500 million. Nine-month BRIUMVI U.S. net product revenue was $655.1 million. These are company targets, not results. Q3 release.
Guidance has been raised three times this year, on May 6, August 3 and November 9, and the sequence is worth setting out because it is the cleanest available evidence on how the launch is tracking against the company’s own expectations.
On February 26, 2026, with the full-year 2025 results, TG guided to total global revenue of approximately $875 to $900 million for 2026 and BRIUMVI United States net product revenue of approximately $825 to $850 million. On May 6, 2026 those became approximately $925 million and $885 to $900 million. On August 3, 2026 they became approximately $950 million and $890 to $905 million.
The quarterly targets were beaten in both quarters for which one was given. The first-quarter target of about $185 to $190 million of BRIUMVI United States revenue came in at about $194.8 million; the second-quarter target of about $220 million came in at $227.7 million. The August release provides annual guidance rather than a Q3 revenue target.
The cost side of the same guidance moved in the same direction, which is the part that gets less attention. Full-year operating expense, defined by the company as research and development plus selling, general and administrative and excluding non-cash compensation, went from “approximately $350 million” in February and May to “approximately $350 – $400 million” in August, on top of approximately $100 million of subcutaneous manufacturing and second-manufacturer start-up costs. Between May and August, revenue guidance rose by $25 million, while the upper end of the expense guidance rose by $50 million. On November 9 the company reaffirmed operating expense guidance of approximately $450–500 million, which includes the subcutaneous manufacturing and secondary-manufacturer start-up costs.
Beyond 2026 there is no numerical guidance at all. What exists is a statement by the chairman and chief executive, Michael S. Weiss, in the August 3 release: the second quarter puts the company “on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate”. That is an exit run rate, not a 2027 revenue target, and it is a forward-looking statement by management rather than a reported figure. It is quoted here as such.
2026 global revenue guidance
887.5MFeb 26, 2026
925MMay 6, 2026
950MAug 3, 2026
~1,000MNov 9, 2026
USD millions; February bar is the midpoint of the $875–900 million range; the November bar is the approximately $1 billion target. Guidance, not actual results.
Source: TG SEC · February / May / August / November 2026
06 ENHANCE, the Consolidated Infusion, and Why There Is No PDUFA Date
Status at November 9, 2026. The company presented full ENHANCE results at MSToronto2026, showing bioequivalent exposure between the approved two-infusion initiation and a single 600 mg initiation infusion, and now guides to a potential launch of the simplified IV initiation in mid-2027, subject to FDA approval. The third-quarter release and Form 10-Q do not report a supplemental filing date or an FDA action date. Q3 release · Form 10-Q.
Three separate programs exist to make BRIUMVI easier to give. The first has already read out.
ENHANCE is a Phase 3, randomized, double-blind, placebo-controlled trial testing whether the two-visit start can be collapsed into one. The primary endpoint was bioequivalence of total drug exposure between the approved regimen — 150 mg on day 1 followed by 450 mg on day 15 — and a single consolidated 600 mg infusion on day 1, measured as area under the curve to week 16 and compared as a geometric mean ratio.
On May 27, 2026 the company announced that ENHANCE met its primary endpoint, with a geometric mean ratio of approximately 1.0 and a 90 percent confidence interval inside the predefined bioequivalence bounds of 0.80 to 1.25. Secondary endpoints on safety, B-cell depletion and imaging were consistent with prior studies. No infusion reactions of grade 3 or higher occurred in either arm, and infusion reactions were lower than those reported in ULTIMATE I and II, with fewer in the single-infusion arm although the difference between arms was not statistically distinguishable.
The May 27 announcement explicitly targeted an ENHANCE supplemental BLA filing in H2 2026. A submission target is not proof of filing, acceptance or a PDUFA date. As of November 18, 2026 the company had not announced an accepted ENHANCE or SC application or an FDA decision date. Previously approved label supplements are separate. Primary source
A related set of data sits in the same category. In November 2024 the company reported that rapid 30-minute infusions were well tolerated, with all infusion-related reactions mild and resolving, and that patients already B-cell depleted on a prior anti-CD20 therapy could switch directly to 450 mg given over one hour without the 150 mg starting dose, with 97 percent of infusions completed without interruption. Neither schedule is in the label. Table 1 still specifies four hours for the first infusion. No regulatory filing has been announced for the 30-minute infusion.
07 Subcutaneous BRIUMVI: The Largest Call Option the Company Owns
On June 3, 2026 TG reported Phase 1 results for a high-concentration 400 mg in 2 mL subcutaneous formulation of ublituximab. More than 100 patients were treated in the study, of whom more than 80 received the subcutaneous route across doses from 50 mg to 400 mg, with over 225 subcutaneous injections given and more than three quarters of them at the full 400 mg. Mean bioavailability was greater than 60 percent relative to intravenous administration, with the lower bound of the 95 percent confidence interval above 55 percent. Kinetics were linear across the dose range.
Local injection-site reactions occurred in fewer than 5 percent of patients and systemic injection-related reactions in about 21 percent, not dose-dependent, mostly at the first injection, and resolving in all patients. No serious injection-site reactions and no new safety signals were reported.
The Phase 3 is NCT07211633, a randomized, open-label, parallel-group non-inferiority study with three arms: intravenous BRIUMVI on the approved schedule, subcutaneous 400 mg every eight weeks, and subcutaneous 400 mg every twelve weeks. The primary endpoint is exposure to week 24, with non-inferiority declared if the lower bound of the 90 percent confidence interval of the geometric mean ratio exceeds 0.80. Enrollment is complete. Modeling from the Phase 1 data projects a geometric mean ratio of about 1.21 for the quarterly regimen with a lower bound of 1.15, and about 1.58 for the every-eight-weeks regimen with a lower bound of 1.50.
Topline is guided for year-end 2026 or the first quarter of 2027. Weiss has spoken of advancing toward a potential approval in 2028. A device bridging study for an autoinjector, NCT07503873, has been recruiting since April 2026 with primary completion estimated for July 2027.
The strategic claim attached to this program — that a subcutaneous option “could nearly double the addressable market opportunity for the BRIUMVI franchise” — is a company statement about an unapproved product and is reported here as that, not as an independent estimate. What can be said without stretching is that the competitive target is specific: Kesimpta (ofatumumab) from Novartis, the anti-CD20 that patients administer themselves at home. Ocrevus Zunovo, the subcutaneous ocrelizumab from Genentech, is given by a healthcare professional and sits in a different position.
08 Myasthenia Gravis, Schizophrenia and What Is No Longer in the Pipeline
Two new indications entered the clinic in the space of two months, both using the approved molecule in diseases where B-cell depletion has a mechanistic rationale.
Myasthenia gravis. The company reports a randomized Phase 2 evaluating IV BRIUMVI maintenance after efgartigimod induction. NCT07673744 lists recruiting status and 120 planned participants. Its September 22, 2026 update moved the estimated start to October 1, 2026; estimated primary completion remains July 1, 2028. Recruiting status and an estimated start are not confirmation that the first patient has been dosed. The August results release also characterizes earlier SC Phase 1 MG data as positive; that headline does not show successful Phase 2 efficacy or a new approved indication.
Schizophrenia. NCT07680946 is a Phase 2 in treatment-resistant schizophrenia, with 60 participants planned. The September 23 registry update gives an actual start of July 27, 2026 and estimated primary completion December 12, 2028. This remains an early immunological hypothesis; no efficacy results had been reported as of November 18, 2026.
The pediatric relapsing-MS program NCT07220252 is recruiting, with 240 participants planned and estimated primary completion January 2030. Planned enrollment is not a count of patients already treated.
These expansion programs have longer development horizons than the upcoming subcutaneous readout. Estimated primary-completion dates do not show when interim data or a final publication will appear; the company has not given a precise readout date for these indications.
09 Azer-cel: The Only Asset That Is Not Ublituximab
Azer-cel, azercabtagene zapreleucel, is the one asset in the pipeline that is not ublituximab. It is an allogeneic, off-the-shelf CAR-T directed at CD19, built from donor T cells using the ARCUS genome-editing technology and designed to avoid graft-versus-host disease.
The Precision license covers autoimmune disease and other non-oncology indications. The initial $7.5 million comprised $5.25 million cash and a $2.25 million equity investment in Precision; a further $2.5 million equity investment followed in January 2025. Milestone 1 was achieved and paid on February 23, 2026: another $7.5 million, split $5.25 million cash and $2.25 million equity investment. That completed payment is not an additional future obligation. Further contingent development and commercial payments and royalties remain under the license.
The FDA cleared the autoimmune azer-cel IND in 2024. The live NCT06680037 record, updated September 9, 2026, lists an actual study start of May 6, 2025, recruiting status, 100 planned participants and estimated primary completion December 1, 2026. A registry start is not necessarily the date of first dosing. The long-term follow-up record NCT07577583 remains not yet recruiting, with an estimated May 2027 start. None of these registry dates is a company-announced readout date.
The azer-cel commitment has now been met: TG had committed to present preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026, and did so on October 23. That commitment was made in January and repeated on August 3. It was one of three remaining 2026 pipeline milestones the company listed, the others being the full ENHANCE results (posters released October 21, 2026) and the subcutaneous Phase 3 topline; the azer-cel late-breaking oral took place on October 23, 2026.
Progressive MS is a distinct clinical challenge. The pooled disability endpoint in ULTIMATE did not show statistical significance, but those relapsing-MS trials do not show whether azer-cel works in progressive disease. Small, early Phase 1 observations will require cautious interpretation and longer follow-up.
10 The Third Quarter of 2026, Line by Line
Third quarter of 2026. Product revenue net was $240.0 million (BRIUMVI U.S. $232.6 million, sales to the ex-U.S. partner $7.4 million) and license, milestone, royalty and other revenue $19.9 million, for total revenue of $259.9 million against $161.7 million. Research and development was $51.3 million and SG&A $80.7 million; operating income $85.9 million; interest expense $15.8 million; net income $55.5 million, $0.39 per basic and $0.35 per diluted share, against $390.9 million a year earlier, which included a non-recurring tax benefit of approximately $365.0 million. For nine months, total revenue was $705.2 million and net income $83.0 million. Q3 release · Form 10-Q.
Revenue. Product revenue net was $240.043 million against $159.317 million a year earlier. License, milestone, royalty and other revenue was $19.893 million against $2.392 million. Total revenue $259.936 million against $161.709 million, up 60.8 percent.
Costs. Cost of revenue $42.079 million. Research and development $51.290 million, of which $7.550 million is stock-based compensation. Selling, general and administrative $80.668 million, of which $17.153 million is stock-based compensation. Total costs and expenses $174.037 million against $132.344 million.
Below the operating line. Operating income $85.899 million against $29.365 million. Interest expense $15.819 million against $6.721 million, the consequence of replacing a $250 million loan with a $750 million one. Other income $3.782 million. Net income before taxes $73.862 million, income tax expense $18.399 million, net income $55.463 million. Earnings per share $0.39 basic and $0.35 diluted, on 140.8 million basic and 155.9 million diluted weighted-average shares.
The cascade adds up line by line: 240.043 plus 19.893 gives 259.936; 42.079 plus 51.290 plus 80.668 gives 174.037; 259.936 less 174.037 gives 85.899; 85.899 less 12.037 of net other expense gives 73.862; less 18.399 of tax gives 55.463.
Stock-based compensation across both operating lines totaled $24.703 million in the third quarter ($7.550 million in research and development and $17.153 million in selling, general and administrative), equal to 9.5 percent of revenue (Merlintrader calculation), and $72.528 million in the nine months. It is a real cost of running this company even though it does not consume cash, and the company’s own operating expense guidance is stated before it.
Cash generation. Net cash provided by operating activities was $66.596 million for the nine months, against $44.432 million used in the same period of 2025, a swing of $111.0 million. Purchases of property, plant and equipment were $0.626 million, so free cash flow for the nine months was about $66.0 million (Merlintrader calculation).
The gap between $83.0 million of nine-month net income and $66.6 million of operating cash is working capital: receivables absorbed $111.2 million and inventory $70.6 million, partly offset by growth in payables and accruals and non-cash compensation added back.
Q3 operating cost structure
Cost of revenue42.079M
R&D51.290M
SG&A80.668M
USD millions; Q3 2026 total costs by line.
Source: TG SEC · Q3 2026
11 The Blue Owl Loan and a Balance Sheet That Changed Shape
September 30, 2026. Cash, cash equivalents and investment securities, excluding equity investments, were $556.7 million, of which $429.4 million in cash and equivalents. The 2026 Term Loan of $750 million principal, maturing March 18, 2031, was carried at $745.6 million net of issuance costs; quarterly amortization of $37.5 million is scheduled from the quarter ending March 31, 2030, and the company reported compliance with all financial covenants. Operating activities provided $66.6 million over nine months. The company states that existing cash and investments, with projected revenue, are sufficient for more than twelve months after the filing, and that it does not currently expect to need additional capital for ongoing operations. Form 10-Q.
Cash, equivalents and investment securities stood at $572.8 million on March 31, 2026, according to the first-quarter 2026 results release, May 6, 2026.
The balance sheet changed shape completely in March 2026, and the change is the most consequential financial event of the year for this company.
On March 18, 2026 TG drew a $750 million term loan under a First Amendment to its financing agreement with Blue Owl, using part of the proceeds to repay in full the $250 million initial term loan taken in August 2024. The new facility matures March 18, 2031. Quarterly amortization of $37.5 million begins with the quarter ending March 31, 2030, with a balloon at maturity, and those installments can be deferred if a total net leverage ratio falls below an agreed threshold. Pricing starts at 4.75 percent over the SOFR-linked option, with a 25 basis point step-down on reaching a leverage threshold, reset quarterly. The loan is secured on substantially all assets of the company and certain guarantor subsidiaries. An additional uncommitted facility of up to $250 million sits alongside it. At September 30 the company stated it was in compliance with all financial covenants.
The refinancing generated a $9.153 million accounting loss on extinguishment in Q1, which is not a cash repayment fee of the same amount. New financing costs were approximately $4.9 million. The term loan carrying value was $745.634 million at September 30, 2026 after unamortized discounts and issuance costs.
The $750 million term-loan principal less $556.7 million cash, equivalents and investment securities gives approximately $193.3 million net term debt (Merlintrader calculation). This definition excludes the legacy convertible notes described below, which carry no cash repayment obligation. Equity was $572.127 million at September 30 versus $648.020 million at December 31, despite positive income in the first nine months, with repurchases affecting equity.
Legacy 5% convertible notes have $15.5 million principal and a $1,125 conversion price; the Form 10-Q lists 23,977 shares issuable on conversion in its dilution table. The filing explicitly states no cash repayment obligation; their fair-value liability was $1.301 million. They are distinct from the cash-pay term loan. In September 2026 Hercules Capital exercised its remaining warrants, covering 115,042 shares at $17.95 and 50,172 shares at $14.70, on a cashless basis; no warrants remained outstanding at September 30, 2026.
The automatic Form S-3ASR shelf filed August 8, 2025 was effective on filing and registered an unspecified amount of debt, equity and other securities. The nine-month cash flow statement in the Form 10-Q shows no proceeds from equity offerings, only $1.1 million from option exercises. Shelf registration permits potential offerings; it does not supply cash, assure investor demand or override offering terms, applicable restrictions or market conditions. Future equity issuance could dilute holders, while debt issuance would add obligations.
12 A Share Count That Is Shrinking, and Q2 and Q3 Buyback Activity
Third quarter of 2026. The company repurchased 2,023,452 shares at an average $49.43, about $100 million. At September 30, 2026 it had used approximately $200 million of the $300 million 2025 program, at an average $37.37, and held 8,894,998 shares in treasury at a cost of about $300.2 million; no warrants remained outstanding. The Form 10-Q cover reports 151,147,827 shares outstanding on November 4, 2026, against 153,069,053 on August 3. Form 10-Q.
The June 30 Form 10-Q also identifies approximately $100 million repurchased under the 2025 program at an average $30.44 per share, distinct from the earlier program’s average price. Form 10-Q for the quarter ended June 30, 2026.
Shares outstanding fell from 155,305,953 at December 31, 2025 to 151,147,827 at November 4, 2026. At September 30, 2026 there were 151,159,605 shares outstanding and 8,894,998 treasury shares, against 155,305,953 outstanding and 3,543,643 treasury at December 31, 2025. Repurchases more than offset issuance over that period. Weighted-average diluted shares fell from approximately 161.0 million in the third quarter of 2025 to 155.9 million in the third quarter of 2026.
The first $100 million repurchase program was completed in September 2025, purchasing 3,502,334 shares at an average $28.55. Repurchased shares should not automatically be called retired: treasury shares remained on the June balance sheet. The second program was increased to $300 million in March 2026; roughly $100 million had been spent by June 30, with treasury stock totalling 6,871,546 shares at $200.2 million cost; by September 30 it was 8,894,998 shares at $300.2 million.
The repurchase program had approximately $100 million of its $300 million authorization remaining at September 30, 2026, after about $100 million of repurchases in the third quarter (Merlintrader calculation). Future repurchases remain discretionary and compete with development and other cash needs.
At September 30, 2026 there were 11,049,049 restricted shares, 4,024,156 options and approximately 1,972,380 stock tracking units outstanding; the Form 10-Q counts 41,625 of the tracking units as potentially dilutive in its earnings-per-share table. These counts are not additive incremental dilution: restricted shares can already be included in issued shares, while options require exercise and tracking units may settle in cash or shares. Tracking-unit expense was $12.9 million in the third quarter and $34.3 million in the nine months.
Reported insider activity needs the transaction code and footnote. The September 14 Form 4 reports Laurence Charney sold 5,000 shares on September 10 at a weighted-average $54.96. Its footnote says the restricted-stock administrator sold them to satisfy his income-tax obligations. Merlintrader reading: this is a reported sale to cover taxes, not evidence of a discretionary bearish view. September Form 4
13 Market Data, Ownership and Retail Sentiment
Market data as of October 2, 2026 (the share count predates the 151,147,827 shares reported on November 4): shares 153.08M, float 141.64M, short float 21.29% (30.15M shares short), short ratio 14.70; institutional ownership 72.96%, insider ownership 7.47%. Third-party figures can lag underlying filings; the data date is not the short settlement date. Ownership reports may overlap and do not form an exclusive allocation of the capital.
The April proxy reports BlackRock 20,134,882, Vanguard 15,596,480 and State Street 8,100,619 shares. BlackRock’s Schedule 13G/A filed October 27, 2026, with a position date of September 30, 2026, reports 21,190,534 shares, or 13.8% of the class. Michael Weiss’s 11,544,752 beneficial shares include 5,995,707 unvested restricted shares and 1,766,666 option shares: this is not the same as freely tradable stock.
Vanguard’s March zero-share amendment reflected an internal reporting reorganization. Vanguard Portfolio Management’s April filing for 8,400,210 shares has a different reporting scope; it does not by itself prove a sale from 15.6 million to 8.4 million.
Retail discussion reflects opinion and attention; it does not show a clinical result, regulatory approval or commercial demand.
14 The Anti-CD20 Field and Where BRIUMVI Sits in It
The principal approved anti-CD20 competitors listed by TG comprise three products based on two other antibodies: ocrelizumab in intravenous and subcutaneous presentations, and ofatumumab.
OCREVUS, ocrelizumab, Genentech, BLA 761053, approved March 28, 2017, intravenous. OCREVUS ZUNOVO, ocrelizumab with hyaluronidase, Genentech, BLA 761371, approved September 13, 2024, subcutaneous and administered by a healthcare professional. KESIMPTA, ofatumumab, Novartis, approved for multiple sclerosis on August 20, 2020 as supplement 70 to BLA 125326, subcutaneous and self-administered by the patient.
The 2025 Form 10-K states the position in the company’s own words: BRIUMVI directly competes with ocrelizumab, the only other approved intravenously administered anti-CD20 antibody, and with the subcutaneous version of ocrelizumab given by healthcare providers; it also competes with ofatumumab, and ofatumumab “would represent direct competition for any future self-administered subcutaneous formulation of ublituximab currently under development”.
A potential home-administered ublituximab presentation would compete particularly with self-administered ofatumumab, while remaining part of the broader anti-CD20 market. Every-eight- or every-twelve-week dosing is investigational; commercial differentiation depends on successful trials, approval, access and adoption.
The 2025 annual report also identifies BTK inhibitors and CD40-ligand approaches as emerging competitive risks. This is the company’s dated competitive assessment, not a real-time regulatory-status statement for every asset in those classes.
Two clarifications for accuracy. Rituximab is not FDA-approved for multiple sclerosis; it is used off-label in some settings and the company does not list it among approved competitors. And the company’s filings and releases give no market share figure for the anti-CD20 class; the only related statement on record is a management objective, not a measurement.
15 The Catalyst Map to 2028
The forward calendar below separates company guidance from estimated registry completion dates. Neither type is an FDA decision date.
| Window | Event | Status |
|---|---|---|
| H2 2026 | Full ENHANCE results (posters released October 21; primary endpoint met, as announced in May) and preliminary azer-cel results | azer-cel data presented October 23, 2026 at MSToronto2026; ENHANCE consolidated-regimen poster presented October 22 |
| Year-end 2026 / Q1 2027 | SC Phase 3 topline, NCT07211633 | Company window; October 31 registry completion is not a readout |
| November 9, 2026 | Third-quarter 2026 report | Reported: revenue $259.9 million, net income $55.5 million, guidance raised to about $1 billion |
| Mid-2027 | Potential launch of simplified single-infusion IV initiation | Company expectation; subject to FDA approval |
| July 31, 2027 | Autoinjector study primary completion | Registry estimate, not a result announcement |
| 2028 | Potential SC launch | Company expectation; conditional on approval, not an FDA decision date |
| July 1, 2028 / December 12, 2028 | MG / schizophrenia primary completion | Registry estimates; interim results may have other timing |
The September 21 updates list ENHANCE as recruiting with estimated primary completion January 21, 2027, and SC Phase 3 as active, not recruiting, with estimated primary completion October 31, 2026. The broader ENHANCE record and its randomized cohort reported in May have different scopes. These completion estimates are not announced result-release dates.
16 Risks and Red Flags
Concentration. One product, one country, about 97 percent of net product revenue. Every operational risk that attaches to BRIUMVI attaches to the whole income statement at once.
Leverage. $750 million of secured debt against $556.7 million of cash, equivalents and investment securities. Interest expense more than doubled year on year to $15.8 million in the third quarter, although operating income of $85.9 million covered it about five times. Amortization of $37.5 million a quarter begins in 2030. The loan is secured on substantially all assets.
Working capital. Receivables and inventory grew substantially in the first nine months. The approximately 144-day closing-balance-to-quarterly-sales proxy is not a reported collection period. Cash conversion requires monitoring even while accounting revenue grows.
Royalty and margin. In the second quarter, LFB royalty expense of $24.4 million was approximately 59% of that quarter’s $41.2 million cost of revenue (Merlintrader calculation). The tiered worldwide royalty affects economics, but margin also depends on product and geographic mix and other manufacturing costs.
Spending ahead of evidence. The company expects approximately $100 million of manufacturing expense in 2026 for the SC program and work with a secondary manufacturer. An unsuccessful pivotal study could reduce the value of part of this investment; the amount is a 2026 forecast, not a perpetual annual commitment or proof that every dollar depends on one trial.
Shelf capacity. The automatic S-3ASR provides financing flexibility but does not show an imminent issuance. Any issue remains subject to applicable law, contractual terms and company decisions.
Label and safety. The current U.S. label is revised January 2026 and includes infection, hepatitis B, immunoglobulin and liver-injury precautions. The registrational program recorded three infection-related deaths. Clinical and regulatory success does not remove these treatment risks.
Governance signal. At the June 11, 2026 annual meeting all directors were re-elected, but two drew unusually high withheld votes: Sagar Lonial at 54.85 percent for and 45.15 percent withheld, and Kenneth Hoberman at 65.52 percent for and 34.48 percent withheld. The advisory executive-compensation proposal was not approved. The company has only two executive officers, and the chairman is also chief executive and president.
Rumor risk. Takeover speculation appears in retail discussion, but as of November 18, 2026 the company had not announced any transaction. Posts do not show a deal or explain how much of the share-price movement it caused.
Merlintrader Health Score · $TGTX
3.9out of 5
Assessed November 9, 2026, after the third-quarter report and Form 10-Q. Weighted calculation: 3.5×30% + 4.0×30% + 4.5×20% + 3.0×10% + 4.5×10% = 1.05 + 1.20 + 0.90 + 0.30 + 0.45 = 3.9. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Financial balances keep their reporting dates and are not current cash.
- The approximately $1 billion revenue target is company guidance, not a reported result: the fourth quarter has to deliver it.
- A subcutaneous approval, its timing and any launch remain subject to Phase 3 results and FDA review.
- Milestone and royalty income is conditional; per-share outcomes depend on issuance and repurchases.
TGTX Stock FAQ: TG Therapeutics Questions Answered
When is the next TG Therapeutics TGTX stock catalyst?
After the third-quarter 2026 report of November 9, 2026, the next dated item in company guidance is subcutaneous BRIUMVI Phase 3 topline, expected at year-end 2026 or early 2027. TG Therapeutics also points to a simplified single-infusion IV initiation with a potential launch in mid-2027 and a subcutaneous launch in 2028, both subject to FDA approval. Third-quarter release.
Is TG Therapeutics’ BRIUMVI FDA approved?
Yes: as of November 9, 2026, intravenous BRIUMVI (ublituximab-xiiy) is approved for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Its investigational subcutaneous formulation and azer-cel program have separate development paths. Approved indication and prescribing information. Development programs.
How much cash does TG Therapeutics have, and how long will it last?
At September 30, 2026, TG Therapeutics held $556.7 million in cash, cash equivalents and investment securities, down from $612.3 million at June 30 after about $100 million of share repurchases in the quarter. The company said on November 9, 2026 that these resources, combined with projected BRIUMVI revenue, are sufficient to fund its business under the current operating plan. Cash position and funding statement.
Is TGTX stock at risk of dilution?
Shares outstanding were 151,147,827 at November 4, 2026, against 153,069,053 at August 3. In the third quarter of 2026 the company repurchased about $100 million of stock, roughly 2.0 million shares at an average $49.43, taking cumulative repurchases to $300 million, or about 6% of shares outstanding at an average $33.88. Stock options and equity awards can still add shares (no warrants remained outstanding at September 30, 2026), and the secured term loan adds interest and repayment obligations. Share repurchase update.
When does TG Therapeutics report earnings?
TG Therapeutics reported third-quarter 2026 results on November 9, 2026: total revenue of $259.9 million, net income of $55.5 million and full-year total revenue guidance raised to approximately $1 billion. The next scheduled report is the fourth quarter. Third-quarter results.
What does TG Therapeutics do?
TG Therapeutics develops and sells treatments for B-cell diseases. Its commercial product BRIUMVI is a CD20-directed antibody for relapsing multiple sclerosis and supplies most product revenue. Development includes a subcutaneous BRIUMVI formulation, additional immune-disease indications and the investigational allogeneic CD19 CAR-T therapy azer-cel. Commercial product and pipeline.
What changed in TG Therapeutics’ third-quarter 2026 results?
TG Therapeutics reported on November 9, 2026 that third-quarter revenue rose to $259.9 million from $161.7 million a year earlier and operating income to $85.9 million from $29.4 million. Net income was $55.5 million, or $0.39 per basic share, against $390.9 million a year earlier, which included a non-recurring tax benefit of about $365.0 million. BRIUMVI U.S. net product revenue was $232.6 million, about 52% higher, and the company raised full-year 2026 total revenue guidance to approximately $1 billion while repurchasing about $100 million of stock in the quarter. Third-quarter 2026 results.
What did TG Therapeutics’ azer-cel study show in progressive MS?
On October 23, 2026, TG Therapeutics reported initial Phase 1 azer-cel results in progressive multiple sclerosis, including stable or improved disability scores in most evaluable participants at Day 90. This small, uncontrolled early study provides preliminary evidence; dose escalation and longer follow-up are continuing. Initial Phase 1 results.
Primary sources
- Form 8-K exhibit 99.1, third-quarter 2026 results and raised full-year guidance, November 9, 2026
- Form 8-K, third-quarter 2026 results, November 9, 2026
- Form 10-Q for the quarter ended September 30, 2026, filed November 9, 2026
- TG Therapeutics — announcement of the conference call on third-quarter 2026 results and business update, November 2, 2026
- TG Therapeutics — schedule of data presentations at MSToronto2026, October 8, 2026
- Form 8-K exhibit 99.1, second-quarter 2026 results and revised guidance
- TG Therapeutics Form 10-Q for the quarter ended June 30, 2026 (SEC)
- Form 8-K, First Amendment to the Blue Owl financing agreement
- Form 8-K exhibit 99.1, positive topline Phase 3 ENHANCE results
- Form 8-K exhibit 99.1, Phase 1 subcutaneous ublituximab data
- Form 8-K exhibit 99.1, 2025 revenue and initial 2026 guidance
- Annual Report on Form 10-K for the year ended December 31, 2025
- Definitive proxy statement on Schedule 14A
- Automatic shelf registration statement on Form S-3ASR
- European Medicines Agency, European public assessment report for Briumvi
- ClinicalTrials.gov NCT07211633
- ClinicalTrials.gov NCT06680037
- ClinicalTrials.gov NCT03277261 (ULTIMATE I)
- ClinicalTrials.gov NCT03277248 (ULTIMATE II)
- Steinman L, Fox E, Hartung HP et al., New England Journal of Medicine 2022;387(8):704-714
- Form 4, Laurence Charney, director — September 14, 2026
- BRIUMVI U.S. prescribing information, January 2026
- Biotech Stock Hubs & Catalyst Index 2026
- Top Ten Biotech Stocks Right Now
- Free Biotech Catalyst Calendar
- October 23 azer-cel Phase 1 presentation highlights
- October 27 Schedule 13G/A; position September 30
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $TGTX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
TG Therapeutics derives most revenue from BRIUMVI, carries $750 million of secured term-loan principal and expects approximately $100 million of manufacturing expense in 2026 for the investigational SC program and a secondary manufacturer. Development, commercial and financing risks can materially affect the value of the shares.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



